EQS-Adhoc

LifeWatch AG: FDA clearance for its Mobile Cardiac Telemetry 1-Lead Patch

EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval
LifeWatch AG: FDA clearance for its Mobile Cardiac Telemetry 1-Lead Patch

18.01.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

LifeWatch receives FDA clearance for its Mobile Cardiac Telemetry 1-Lead
Patch

Zug/Switzerland, January 18, 2016 - LifeWatch AG (SIX Swiss Exchange:
LIFE), a leading developer and provider of medical solutions and remote
diagnostic monitoring services to the digital health market, is pleased to
announce that it has received U.S. Food and Drug Administration (FDA) 510k
clearance for its internally-developed LifeWatch Mobile Cardiac Telemetry
(MCT) Patch, a 1-lead ECG system.

The LifeWatch MCT 1-Lead Patch is the newest addition to LifeWatch's
cardiac diagnostic monitoring offering, and continues to build on
LifeWatch's commitment to becoming a truly global provider of remote
diagnostic monitoring devices and services.

This latest clearance, when combined with the recently obtained CE mark,
enables LifeWatch to provide patients in many parts of the globe with a new
diagnostic monitoring patch alternative. The MCT 1-Lead Patch is capable of
watching every heartbeat for adverse cardiac events and transmitting
significant findings, in near real time, to a clinical service center for
immediate follow-up. The MCT 1-Lead Patch technology is an easy to use,
discrete and lightweight alternative to traditional recording and
transmitting devices. It is significantly more comfortable for the patient
and should therefore lead to an increase in the diagnostic yield as a
result of improved patient compliance.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "I am very excited about
this milestone which will now allow us to introduce our patch technology to
a broader market. The FDA clearance represents yet another significant
achievement for LifeWatch and further strengthens our position as an
innovational leader in digital health."


For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: [phone]
E-mail: [e-mail]


About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),

Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote
diagnostic patient monitoring services. LifeWatch's services provide
physicians with critical information to determine appropriate treatment and